Literature DB >> 3753579

RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions.

I J Stratford, P O'Neill, P W Sheldon, A R Silver, J M Walling, G E Adams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3753579     DOI： 10.1016/0006-2952(86)90566-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  12 in total

Review 1.  Modulation of the tumor vasculature and oxygenation to improve therapy.

Authors:  Dietmar W Siemann; Michael R Horsman
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

2.  Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.

Authors:  M I Walton; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).

Authors:  M Binger; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  High uptake of RSU 1069 and its analogues melanotic melanomas.

Authors:  J M Walling; J Deacon; S Holliday; I J Stratford
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  NAD(P)H nitroblue tetrazolium reductase levels in apparently normoxic tissues: a histochemical study correlating enzyme activity with binding of radiolabelled misonidazole.

Authors:  L M Cobb; T Hacker; J Nolan
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

6.  The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.

Authors:  A Keohane; J Godden; I J Stratford; G E Adams
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

Review 7.  SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.

Authors:  J M Brown
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

8.  Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).

Authors:  D J Chaplin
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

9.  Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

Authors:  A V Patterson; H M Barham; E C Chinje; G E Adams; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

10.  Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.

Authors:  B G Siim; P L van Zijl; J M Brown
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.